International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 1047-1065 www.ijprajournal.com ISSN: 2456-4494

Therapeutic Potency of IV Ferricpyrophospatein Chronic Kidneydisease

*[1]Sourav Dhibar, [2]Ashna Kohli
[1]Student,[2]Assistant Professor, Kukreja Institute of Pharmaceutical Science, Jhajra , Uttarakhand , INDIA

Submitted: 26-05-2022 Revised: 03-06-2022 Accepted: 06-06-2022

ABSTRACT
Chronic kidney disease (CKD) is a prevalent clinical condition among the elderly, and it is linked to an increased risk of morbidity and mortality. Glycemic iron supplementation with ferric pyrophosphate citrate has been reported to lower the dosage of erythropoiesis-stimulating drugs and intravenous iron supplementation while increasing serum ferritin levels.For the treatment of IDA in patients with CKD, we review the existing oral and intravenous (IV) iron formulations.The use of ferric pyrophosphate is based on the assumption that such different species create a strong aggregate. Iron is donated directly to transferrin by IV ferric pyrophosphate citrate (FPC, Triferic®), bypassing the reticuloendothelial system and avoiding iron sequestration. IV Ferric pyrophosphate citrate is used to treat iron deficiency and loss of haemoglobin, as well as to lower the amount of erythropoiesis-stimulating agent (ESA) needed to maintain target haemoglobin levels. The possible risks and advantages of IV vs oral iron supplementation in patients with CKD are discussed, as well as the potential hazards and benefits of a more liberal approach to iron administration.Furthermore, this study discusses current advances in intravenous iron supplementation as well as future prospects in the treatment of renal anaemia.This drug might be given to patients on hemodialysis with stage 5 chronic renal disease as a novel iron supplementation option to keep haemoglobin, transferrin saturation, and ferritin levels stable.

Key Words: Chronic kidney disease, IV ferric pyrophosphate citrate, Anaemia , Oral Iron Supplementation.

I. INTRODUCTION

Chronic kidney disease (CKD) is a prevalent conical condition among the elderly, and it is linked to an increased risk of morbidity and mortality[5,6]. As global life expectancy rises, the incidence of comorbidities and risk factors such as hypertension and diabetes rises, exposing this population to a high burden of CKD[5,6]. The corpus of information on how to treat elderly CKD patients is continually growing. As a result, the goal of this review is to look into the epidemiology and present current knowledge of problems in the treatment and monitoring of CKD in the elderly[9,10,12].

Glycemic iron supplementation with ferric pyrophosphate citrate has been reported to lower the dosage of erythropoiesis-stimulating drugs and intravenous iron supplementation while increasing serum ferritin levels[11,15,20].This substance may indeed be provided to patients on hemodialysis with stage 5 chronic renal disease as a novel iron replenishmention alternative to keep haemoglobin, transferrin saturation, and ferritin levels stable[3].

The use of ferric pyrophosphate is based on the assumption that such different species create a strong aggregate[5,6,9]. In addition, pyrophosphate has the ability to cause iron elimination from transferrin, improve iron transport through transferrin to ferritin, and stimulate iron exchange between transferrin molecules[17,20]. Such characteristics make it an excellent candidate for topical application, iron transport into vasculature, and haemoglobin inclusion[3,5].

Chronic Kidney Disease

Chronic kidney disease (CKD) is a clinical illness caused by a permanent alteration mostly in kidney's function and/or structure, so it is defined through its arbitrariness yet gradual and steady progression[6,9]. Some other essential element is that the abnormality is associated with a greater risk of morbidity and death, particularly aerobic endurance consequences and fatalities[1].

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 1047-1065 www.ijprajournal.com ISSN: 2456-4494



FIG-1: PRE- AND POST-STROKE PROBLEMS ARE CAUSED BY CKD. EENDOGENEOUS TPA/PAI-1, MMP-9, UREMIC TOXINS SUCH AS INDOXYL SULPHATE, P-CRESYL SULPHATE, AND GUANIDINO COMPOUNDS, AS WELL AS PROFIBROTICS SUCH AS TGF-B1, TENASCIN-C, PAI, ANG-II, AND CONCOMITANT DISEASES SUCH AS HYPERTENSION AND DIABETES, CAUSE CKD TO DEVELOP FROM PHASE 1 TO PHASE 5. ENDOTHELIAL DYSFUNCTION, VASCULAR STIFFNESS, BBB DISRUPTION, AND PERIPHERAL/CENTRAL INFLAMMATION ALL WORSEN AS CKD PROGRESSES. BOTH BEFORE AND AFTER A STROKE, THEY HAVE SERIOUS REPERCUSSIONS IN THE BRAIN[15].
PAI-1 IS FOR PLASMINOGEN ACTIVATOR INHIBITOR-1, MMP-9 STANDS FOR MATRIX METALLOPROTEINASE-9, ESRD STANDS FOR END-STAGE RENAL DISEASE, BBB STANDS FOR BLOOD–BRAIN BARRIER, AND RTPA STANDS FOR RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR[15].

Chronic kidney disease (CKD) is described by a latest "Kidney Disease Enhancing Worldwide Achievements" (KDIGO) regulations as the appearance about an estimated glomerular filtration rate (EGFR) of less than 60ml/min/1.73m2 (within at least 3 months), or the establishment of microalbuminuria encountered instantly in a kidney endoscopy or tangentially either by appearance of albuminuria, adjustments in urine sediment, or computed tomography[2].

A patient is diagnosed with CKD if theirglomerular filtration rate (GFR) is less than 60 ml/min/1.73 m2 for more than three months, or if their GFR is more than 60 ml/min/1.73 m2 though there is indication of nephro structural harm[1].Albuminuria, abnormalities in glomerular tomography, hematuria/leukocyturia, recurrent hydroelectrolytic diseases, histopathological alterations in biopsy procedure, and prior kidney transplants are all markers of renal damage[1]. The detection of far more over 30 mg of albumin in the 24hr bladder or more than 30 mg/g of albumin in an isolated sample of urine regulated by urinary creatinine indicates albuminuria[1].

Insulin resistance, hypertension, chronic glomerulonephritis, chronic pyelonephritis, chronic anti-inflammatory drug usage, autoimmune illnesses, kidney disorders, Alport disease, congenital anomalies, and prolonged acute renal disease are the most common causes of CKD[1].
Chronic kidney disease (CKD) is a serious public health hazard that affects over 47 million people worldwide, or 16.4% of such adult population in India[3]. It's linked to a lot of health-care expenses, disability, and mortality. 1,2 Endotracheal intubation, cardiac problems, and mortality are all increased when you have CKD[3].

Classification:

The patient's GFR, albuminuria level, and aetiology are all factors in determining their CKD categorization. Table 1 shows the levels of GFR

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 1047-1065 www.ijprajournal.com ISSN: 2456-4494

(G1 to G5) and albuminuria (A1 to A3)[3].There are currently forecasting calculations for assessing renal function, with the formulae including the patient's creatinine, sex, age, and weight. The Chronic Kidney Disease Epidemiology Collaboration Measurement (CKD-EPI) and the Cockcroft-Gault equations are two techniques that are thought to be useful in MDRD research[4,5].

TABLE 1 :CKD CLASSIFICATION[3]

GF Categories

Category	GF (ml/min)	Description
G1	≥90	Normal or elevated
G2	60–89	Slightly diminished
G3a	45–59	Slightly to moderately diminished
G3b	30–44	Moderately to severely diminished
G4	15–29	Severely diminished
G5	< 15	Renal failure

Albuminuria categories (isolated urine sample), mg/g

Category	Albumin/creatinine ratio	Description
A1	<30	Normal to slightly elevated
A2	30–300	Moderately elevated
A3 >	300	Very elevated

espite the increasing use of the GFR as a screening tool in clinical practise, a GFR of 60ml/min/1.73m2 does not always detect the presence of CKD, which could lead to an overdiagnosis of the disease, especially among the elderly[4,5,6].

CKD is defined by a decrease in GFR as well as an acute condition that results in pharmacological abnormalities in a variety of other organs (see the section on Ageing and the mechanisms involved in chronic kidney disease)[8,9]. In this regard, a measure that includes haemoglobin concentration, urea, and gender (HUGE) has been developed to evaluate whether people with a GFR of 60ml/min have renal disease or have a GFR reduction owing to ageing[3,5]. This technique has also been connected to long-term living standards forecasts in non-hospitalized elderly individuals[2,3,5,8].

The current prevalence of CKD in India is estimated to be 9.2 percent of the adult population, with a 6.8 percent general incidence in stages 3–5, but this number jumps to 20.6 percent in patients above 643[11,19]. This increase can be attributed to the fact that this population is older, has higher cardiovascular risk factors, and gets identified earlier[3,5,9].

In contrast to having a greater incidence, which is expected to rise in the future years, CKD is linked to negative pathophysiologic outcomes, as well as a considerable elevation in cardiovascular morbidity and mortality[3].This warrants a significant investment of resources and a significant rising healthcare costs. In India, the utilized to treat advanced stages of CKD is projected to be over D 800 million each year[3].

As a consequence of all of this, there has been a lot of effort in recent decades to diagnose this disorder early in order to halt its progression. Furthermore, whether the client is a candidate for replacement kidney therapy or conservative treatment, as well as if the patient is suitably prepared for diagnostic and therapeutic interventions including such hemodialysis and transplantation, must be decided[6,8,11].

Chronic kidney disease and its mechanisms that are connected to elderly:

There've been explanations of how, around the age of 30, the glomerulus is replaced with fibrous tissue (glomerulosclerosis), which worsens over time.In the overall adult population, CKD is fairly common[3,7].

According to Indian data, there are around 39.4 % of persons aged 60 and over, a figure that has climbed over time. According to a recent review of the study, the prevalence of the disease varies depending on the method used to identify it; using populational criteria, 3-6 million people are predicted to be affected[7,9,13].

Conversely, there seems to be an expansion in glomerular tissue, with predominant obliteration of the juxtamedullary nephrons, as well as subendothelial deposits of hyaline tissue and collagen in the arterioles, thickening of the intima, medial atrophy, and sympathetic vascular impulse failure. Tubules, on either way, experience fat tissue deterioration with growth of the basal membrane, as well as increasing regions of atrophy and fibrosis[3].

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 1047-1065 www.ijprajournal.com ISSN: 2456-4494



FIG.2– THE ADVENT OF FRAILTY IN CKD HAS BEEN LINKED TO A MECHANISM[3]

The physiologic alterations outlined above result in a drop in GFR and a decrease in effective renal plasma flow (ERPF), with a tendency to increase the filtration fraction (the GFR/ERPF ratio)14,18, at the price of a disproportionately reduction in the ERPF denominator comparison to the GFR[11,13].All of these physiological responses account for the decrement in sodium reabsorption, which leads to increased fractional sodium excretion in elderly patients, as well as a reduce in both kidney plasma concentration and response to

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 1047-1065 www.ijprajournal.com ISSN: 2456-4494

stimulus, resulting in medullary hypotonicity and a lower urine concentration capacity[6,8,9].

It is crucial to note that, while a senile kidney will show a sequence of alterations connected with a drop in GFR, this is not the same as the decrease in GFR accompanied with CKD in many ways(Table above shows the result)[3].CKD is linked to an increased risk of coronary heart disease, aggravation, and mortality, in additional to being very common. In fact, according to global data from 2013, a decrease in GFR was linked to 4% of fatalities globally, or 2.2 million deaths. More than half of those who died were due to heart disease, and 0.96 million were due to end-stage renal illness[1].

According to the SBN census, dialysis patients had an annual net rate of death of 19.9%[5].

Symptoms:

Initial symptoms include:

Almost all of the early symptoms of renal failure are similar to those of other diseases and ailments[1-9].

- nausea and vomiting

TABLE 2 – PHYSIOLOGICAL ASPECTS DIFFERENTIATED IN CKD[3]

Senile kidney	CKD	
Proximal tubule function	Preserved	Diminished
Plasma erythropoietin Anaemiaa	Normal. Hb normal	Diminished
Calcium (Ca), magnesium (Mg) and impaired, Mg normal and P elevated phosphorous (P) levels osteoporosisa	Normal	Ca levels Osteopenia and
PTH and Vit. D and Vit. D impaired Renal osteodystrophy and risk of fallsa	Normal	PTH elevated
Urea levels Uraemia (anorexia, encephalopathy, pruritus, oedema, bleeding, polyneuropathy	Normal	Elevated
Fractional sodium excretion (under the influence of aldosterone) Lastly, hyper-K which leads to cardiacarrhythmia	Relatively impaired	Increases as GFR decreases
Urinalysis and/or proteinuria (≥0.3 g/day) Malnutrition, oedema	Normal	Altered, haematuria

GFR: glomerular filtration rate; PTH: parathyroid hormone; Vit. D: vitamin D .
[a]Clinical symptoms related to the physiological changes in CKD.

- loss of appetite
- itching
- chest pain
- uncontrollable high blood pressure
- unexpected weight loss

Symptoms in the latter phases include:

You might ultimately notice symptoms if the damage to your kidneys worsens. However, this may not occur until significant harm has already been done[9].

- difficulty staying alert
- cramps and twitches
- numbness in your limbs
- weakness
- fatigue
- bad breath
- skin that's darker or lighter than usual
- bone pain
- excessive thirst
- bleeding and bruising easily
- insomnia
- urinating much more or less than usual
- hiccups
- swollen feet and ankles
- absent menstrual periods
- shortness of breath

Chronic kidney disease can potentially have catastrophic consequences, including:

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 1047-1065 www.ijprajournal.com ISSN: 2456-4494

- high blood pressure
- fluid buildup in your lungs or other areas
- vitamin D deficiency, which can affect your bone health
- nerve damage that can lead to seizures

Diagnosis:

As a beginning phase toward a kidney medical diagnostics,Ones doctor will talk to you about your individual / family circumstances. Your physician may inquire regarding whether you've been identified with high blood pressure, among many other issues,Once you've consumed a drug that might impair kidney function, if you've seen abnormalities in your urine patterns, or if you have relatives with renal disease, tell your doctor[5,6].

Your doctor will then undertake a medical assessment and a neuropsychological assessment, looking for evidence of heart or blood vessel abnormalities[4].

Several tests and treatments may be required for kidney disease diagnosis in order to evaluate the severity of your kidney disease (stage). The following tests may be performed[7]:

- **Blood tests[7]:**Kidney function tests check for waste materials in your blood such as creatinine and urea.
- **Urine tests[7]:**A urine sample can show anomalies that indicate chronic kidney failure and aid in determining the aetiology of chronic kidney disease.
- **Imaging tests[7]:**Your doctor may use ultrasonography to examine the shape and size of your kidneys. In some circumstances, further imaging tests may be employed.
- **Removing a sample of kidney tissue for testing[7]:**A kidney diagnostic, which includes taking a sample of kidney tissue, may be recommended by your doctor. A long, thin needle is introduced through your skin and into your kidney during a biopsy procedure, which is usually done under local anaesthetic. The biopsy sample is submitted to a lab for examination in order to figure out what's wrong with your kidneys**.**

Treatment:

Some forms of kidney disease can be treated, based on the reason. Chronic renal disease, on the other hand, is frequently incurable[8].

Treatment normally include taking steps to manage indications and sensations, decrease complications, and delay the condition's course. You may need therapy for later part renal disease if your kidneys become severely injured[9].

❖ **Treating the cause:**

Your doctor will try to delay or stop the progression of your kidney disease by treating the underlying cause. Depending on the reason, several treatment approaches are available. Even if an underlying illness, such as diabetes mellitus or high blood pressure, is under control, kidney damage might increase[11].

❖ **Treating complications:**

Complications of kidney illness can be managed to help you feel better. The following are some possible treatment[3]:

- **High blood pressure medications**

RENIN–ANGIOTENSIN–ALDOSTERONE SYSTEM (RAS) INHBITOR

Lewis et al., in 1993, were the first to demonstrate that angiotensin-converting enzyme (ACE) inhibitors might reduce the course of diabetic nephropathy[12].More than 60 years ago, Addis hypothesised that decreasing the excretory load for nitrogen by dietary protein restriction might alleviate the severity of renal illness[13].More than 60 years ago, Addis hypothesised that decreasing the secretion load for nitrogen by dietary protein restriction might alleviate the severity of renal illness[17].

The research was based on animal experiments conducted by numerous laboratories, the most notable of which being Barry Brenner's in the 1980s[19].ACE inhibitors and angiotensin II receptor blockers (ARBs) are standard drugs for primary hypertension. However, they are each especially effective in slowing the progressive decay of GFR in CKD[11-17].

In preclinical studies of CKD characterised by glomerular capillary hypertension which including diminished nephron mass and streptozotocin-induced diabetes, ACE inhibitors diminished glomerular capillary pressure as well as slowed disease progression more effectively than combined therapy with hydralazine, reserpine, and a diuretic at comparable systemic BP control, an impact which was inevitably connected with a consistent decline in proteinuria[7-15].

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 1047-1065 www.ijprajournal.com ISSN: 2456-4494

The disease condition that has been examined the most with these drugs is chronic nephropathy. Stagnating the pace of developing renal damage with renin–angiotensin–aldosterone system (RAAS) inhibition has been linked to the stabilisation or decrease of proteinuria in both type 1 and type 2 diabetes[11-19].

Mechanism	Comment	Mediator
Stimulation of NF-kB	A transcription factor that causes a cascade of cytokines and other proinflammatory mediators to be produced	AngII AngIII,AngIV
Stimulation of ETs-1	T-cell and macrophage/monocyte recruitment is a modulator of vascular inflammation	AngII
Adhesion molecules Vascular cellular adhesion molecule 1 Intracellular adhesion molecule 1 Integrins	Inflammatory cells appear to adhere to capillary walls when this substance is present	AngII
Cell proliferation Mesangial cells Glomerular endothelial cells Fibroblasts	Enhances kidney fibrosis and structural damage	AngII/Aldo
Apoptosis	AngII, rather than causing cellular growth, causes apoptosis in some conditions; how this is controlled is unknown.	AngII
Increased TGF-b expression	An essential protein with cascade effects that are vital in inflammation and fibrosis	AngII/Renin
Increased connective tissue growth factor	TGF-b upregulation or direct AngII stimulation can cause this	AngII
Increased ECM products Type I procollagen Fibronectin Collagen type IV	ECM buildup occurs as a result of several processes, and they are important contributors to fibrosis	AngII
Increased metalloproteinase inhibitors Plasminogen activator inhibitor-1 Tissue inhibitor of matrix metalloproteinases	As a result of the reduced turnove, ECM accumulates	AngII
Ac-SDKP hydrolysis	Fibrosis and inflammatory cell infiltration are increased	ACE
Reactive oxygen species	This induces cellular damage.	Aldo
MAPK activation	Contributes to renal fibrosis and mesangial damage.	AngII/Aldo

TABLE 3| REPORTED NONHEMODYNAMIC EFFECTS OF RENIN–ANGIOTENSIN–ALDOSTERONE SYSTEM[15]

Abbreviations: ACE, angiotensin-converting enzyme; Ac-SDKP, N-acetyl-seryl-aspartyl-lysyl-proline; Aldo, aldosterone; Ang, angiotensin; ECM, extracellular matrix; ETs-1, endothelins-1; MAPK, mitogen-activated protein kinase; NF-kB, nuclear factor k-light-chain-enhancer of activated B cells; TGF-b, transforming growth factor-b.

The antiproteinuric consequences of the ARB losartan in rats with stz - induced diabetic was described by a restored sieve analysis function of the glomerular barrier with a shifting of the pore-size population toward measurements even smaller than those calculated for normal controls, according to fractional clearances of polydisperse

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 1047-1065 www.ijprajournal.com ISSN: 2456-4494

neutral macromolecules of graded molecular size (Ficoll)[3-9].

Aldosterone, along with AngII, adds to the RAAS's negative effects in progressive CKD. Because of the negative consequences of aldosterone, mineralocorticoid receptor blockers have been developed to selectively inhibit it[11-15].In male MWF/Ztm rats that develop extensive proteinuria and glomerulosclerosis in the absence of glomerular capillary hypertension, the ACE inhibitor enalapril exhibited a substantial renoprotective impact[15,16].

In conclusion, blocking the RAAS with ACE inhibitors or ARBs has been shown to slow the course of CKD. Studies are now underway to determine the usefulness of disrupting the route at many locations at the same time, but such techniques have yet to be demonstrated to be more successful than the use of ACE inhibitors or ARBs, and their safety has not been thoroughly studied[6,8,9,11,].

Because hypertension drugs can temporarily impair kidney function and alter electrolyte balance, you may require frequent blood tests to keep track of your progress. A water tablet (diuretic) and a low-salt diet may also be recommended by your doctor[3-9].

Because high blood pressure drugs can reduce kidney function and alter electrolyte balance at first, you may require frequent blood tests to keep track of your progress. A diuretic (water pill) and a low-salt diet may be suggested by your doctor[19,20].

- **Medications to relieve swelling**

Fluid retention is common in people with chronic renal disease. Swelling in the legs as well as elevated blood pressure might result as a result of this. Diuretics are medications that assist keep your body's fluid balance in check[11-23].

Such as meals or oral supplements, as well as exercise regimens offered during dialysis or at home, are viable and economical therapies that might enhance ESRD patients' survival and quality of life. Individual responses to these therapies, on the other hand, may be influenced by initial systemic inflammation[22,26,30].

In adult HD patients with protein-energy wasting, growth hormone is currently considered an anabolic agent[3-9].



FIG.2-INFLAMMATION CAUSES AND EFFECTS IN CHRONIC RENAL DISEASE[31].

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 1047-1065 www.ijprajournal.com ISSN: 2456-4494

Growth hormone is a member of the cytokine family, and its capacity to control the inflammatory response has been a focus of research[12,13].

Growth hormone supplementation in maintenance HD patients resulted in a substantial drop in CRP and homocysteine, as well as an increase in blood HDL cholesterol and transferrin, according to a large multicenter randomised controlled experiment. Growth hormone treatment in children with CKD-related growth failure has yet to be proven to have any anti-inflammatory benefits[21.23.24.26].

Utilisation recognised CKD therapies for broader or non-traditional indications (e.g., growth hormone and vitamin D, as discussed earlier), novel agents to control pathophysiologic mechanisms triggering inflammatory response (e.g., antioxidants), and specific anti-cytokine therapies are all examples of pharmacologic interventions aimed at reducing inflammation in CKD[18,19].

A recent meta-analysis found that using ultrapure dialysate reduces inflammation and oxidative stress indicators, increases serum albumin and haemoglobin, and reduces the need for erythropoietin in HD patients. When compared to traditional HD, short daily dialysis reduced CRP and enhanced erythropoietin attentiveness. A recent meta-analysis found that frequent or prolonged hemodialysis had a positive impact on cardiovascular outcomes. Hemodiafiltration may reduce inflammatory activity by allowing intermediate molecules to be cleared by convection. Den Hoedt et al. discovered that online hemodiafiltration decreased systemic inflammation (CRP and IL-6) when compared to low-flux HD in a large dataset from the randomised controlled Convective Transport Study (CONTRAST)[10,14,26,31].

Recognizing the involvement of inflammation in CKD will aid in the development of therapeutic solutions to treat and perhaps prevent the underlying inflammation, hence enhancing CKD consequences[30,31].



FIG.3-THE UREMIC METABOLITES (TMAO, P-CRESYL SULPHATE, AND INDOXYL SULPHATE) FOLLOW THIS ROUTE IN THE UREMIC MILIEU, WHICH IS DIAGNOSTIC OF CKD. BY BOOSTING THE BACTERIA TYPES THAT CREATE UREMIC TOXINS, GUT MICROBIOTA DYSBIOSIS LEADS TO THE CREATION OF A PROTEOLYTIC FERMENTATION PATTERN[29].

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 1047-1065 www.ijprajournal.com ISSN: 2456-4494

- **Medications to treat anemia**

Iron supplements can aid in the production of healthy red blood cells in the body. These supplements can be consumed orally or by IV infusion. If you're on dialysis, you can have an iron infusion at the same time as your dialysis[31-35].When your kidneys are injured, they generate less erythropoietin (EPO), a hormone that tells your bone marrow to manufacture red blood cells. Your body produces fewer red blood cells when you have less EPO, and oxygen is transported to your organs and tissues is reduced[39-41].TREAT randomised 4038 people with CKD caused by type 2 diabetes to either a target haemoglobin of 13 g/dl or a placebo with darbepoieten rescue if the level went below 9 g/dl[42].For both groups, the baseline eGFR was B35 ml/min per 1.73 m2. There were no changes in cardiovascular or renal outcomes between the two groups except for more strokes in the higher haemoglobin group. Over the course of the four years of research, around 16 percent of the patients in each group had ESRD8[8,12,23,26].A blood transfusion is a rapid approach to boost your red blood cell count in extreme situations of anaemia. However, this is merely a band-aid remedy that does not address the root of the problem[48-49].Ferric pyrophosphate citrate injection is an iron replacement medication used to treat iron deficiency anaemia (a lack of iron in the blood) in patients with chronic renal disease who are on dialysis (CKD)[33,39].

➢ **Current Advances in Oral Iron Supplementation:**

The first-line oral iron therapy is ferrous salts, with ferrous sulphate being the most widely utilised in clinical practise[41,42].Ferrous gluconate, ferrous succinate, and iron polymaltose are some of the other common oral iron supplements.The biggest issue with using oral iron supplements in clinical practise is that most chronic conditions can cause poor absorption and GI side effects[38-44].

FC, ferric maltol, heme iron polypeptide (HIP), and sucrosomial iron are some of the new oral iron agents that have appeared in recent years (SI)[49].These new iron formulations have higher effectiveness and fewer side effects than previous iron preparations, and they are more successful in raising Hgb levels[36].

Furthermore, FC is an authorised phosphate binder for use in dialysis-dependent patients with CKD[42,43,45].The availability of these novel iron compounds expands the therapy options for iron deficiency anaemia (IDA) and allows for a better selection of iron preparations in a variety of clinical circumstances, including IBD, celiac disease, and autoimmune gastritis[55].The following is a list of the new oral iron supplements products (Tabel 4)[55].

- **Ferric Citrate**

FC was originally developed as a non-calcium phosphate binder, but researchers discovered in the phase 2 trial that patients with non-dialysis dependent CKD (NDD-CKD) and even patients with end-stage renal disease (ESRD) on dialysis could absorb most of the iron in the GI tract, improving iron status and Hgb levels[53].

TABLE 4: IN INDIVIDUALS WITH CHRONIC RENAL DISEASE, A SUMMARY OF CURRENT IRON THERAPY IS PROVIDED.

Medications (Dose Strength)	Typical Dosage	Advantages
Oral iron formulations		
Ferric citrate (500 mg/capsule)	Three times a day, 1000 mg (equal to 210 mg iron) with meals	Phosphate control ↓FGF-23; ↑1,25-dihydroxyvitamin D
Ferric maltol (30 mg of iron/capsule)	1 capsule twice a day, 30 minutes before meals	Bioavailability is high. Resistance to lipid peroxidation
Heme iron polypeptide (11 mg of iron/tablet)	1 pill three times a day with meals is recommended.	Absorption via the heme transporter in the intestine
Sucrosomial iron (30 mg of iron/packet)	1 packet after a meal, once a day	Good GI tolerance and unique absorption routes
IV iron formulations		
Ferumoxytol (510 mg of iron/vial)	15-minute administration with 510 mg	Characteristics that are common:
Iron isomaltoside 1000	A 15-minute infusion of 1000	1. Allows for the rapid

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 1047-1065 www.ijprajournal.com ISSN: 2456-4494

(1000 mg of iron/vial)	mg	administration of a slightly elevated IV infusion. 2. Free iron toxicity is quite stable. 3. Infusion responses have low immunogenicity
Ferric carboxymaltose (750 mg of iron/vial)	A 15-minute infusion of 750–1000 mg	
Intradialytic iron formulations		
Ferric pyrophosphate citrate (272 mg iron/packet)	1 packet per 25 litres of concentrated bicarbonate	Dialysate is used to administer the medication. Lacking iron sequestration, iron is transported to transferrin.

Abbreviations: IV, intravenous; FGF23, fibroblast growth factor 23. "↑" (means increase), "↓" (means decrease).

Furthermore, FC has been shown to lower C-terminal and intact fibroblast growth factor 23 (FGF23) levels, which are closely linked to CV disorders and are independent predictors of death in patients with moderate to severe CKD[51-60].

- **Phosphate Control and the Effects of Ferric Citrate**

The dissociated ferric iron binds to phosphorus in the GI tract after oral delivery of FC and precipitates as ferric phosphate[45].This molecule is eliminated in the faeces, lowering phosphate absorption from the food[38,42,50].FC's effectiveness as an iron-containing phosphate binder in lowering blood phosphate levels in patients with various kinds and stages of CKD has been established in several clinical trials[52,58,60].

We found that treatment with FC effectively reduced serum phosphate levels by 1.39 mg/dL (95 percent confidence interval: 0.66 to 2.12) and had a comparable effect compared to active treatment, including calcium-based and noncalcium phosphate binders in phosphate control, in a previous meta-analysis of nine randomised controlled trials (RCTs) involving 1755 patients with CKD stages 3–5 and those on dialysis[60-69].

- **Ferric Citrate's Effects on Iron Status and Hemoglobin Levels**

The intestinal absorption of iron from FC raises serum iron, ferritin, and TSAT levels, resulting in a rise in total Hgb and RBC mass. After oral delivery, DMT1 reduces elemental ferric iron to ferrous iron in each 500 mg of FC (Nephoxil)[71].

Iron can be stored in enterocytes coupled to ferritin or exported into plasma by FPN and made accessible for erythropoiesis after being delivered into enterocytes via DMT1[72-73].Adults with NDD-CKD were studied in a randomised, double-blind clinical study by Fishbane et al. Patients who received FC were considerably more likely than those who received a placebo to have increases in serum ferritin, TSAT, and Hgb levels. The therapeutic impact was shown as soon as 1–2 weeks following the start of the medication[41-46]. T

he effect was long-lasting, and the requirement for ESA and IV iron supplements was significantly reduced[48,49]. The decreased production of reactive oxygen species during iron metabolism leads in superior GI tolerability of FC when compared to standard oral ferrous salts[60].Overall, oral FC might be a safe and effective therapy for IDA in individuals with moderate to severe CKD[65].

- **Ferric Citrate's Impact in Fibroblast Growth Factor 23**

In individuals with CKD, sustained hyperphosphatemia causes a rise in FGF23, a hormone generated by osteocytes that regulates phosphaturia[60,61,62]. Several variables induce the synthesis of FGF23, including changes in calcium, phosphate, parathyroid hormone, and 1-25-dihydroxyvitamin D levels.FGF23 works directly on renal proximal tubules to generate phosphaturia in the early stages of CKD, lowering blood phosphate levels[52,56,60].

High levels of FGF23, on the other hand, are linked to left ventricular hypertrophy, anaemia, and cardiovascular mortality[44].This decrease in FGF23 levels is also seen in those who have normal baseline blood phosphate levels, suggesting that the impact is not driven by phosphate deficiency[38].

Attenuation of inflammation–FGF23 positive feedback loops and modulation of FGF23–1,25-dihydroxyvitamin D interactions are two possible

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 1047-1065 www.ijprajournal.com ISSN: 2456-4494

mechanisms for this effect.The therapeutic relevance of FGF23 decreases generated by FC has to be investigated further[56].However, it is thought that lowering FGF23 will enhance 1,25-dihydroxyvitamin D levels, which will improve bone mineral density and cardiovascular functional capability. Blocking FGF23 activity may also boost positive iron storage and iron consumption, as well as stimulate renal EPO synthesis and ameliorate renal anaemia (Figure4)[58].



FIG.4-ILLUSTRATION OF FERRIC CITRATE'S PUTATIVE MODES OF ACTION (FC). FC BINDS DIETARY PHOSPHORUS IN THE GASTROINTESTINAL SYSTEM, LOWERING SERUM PHOSPHATE LEVELS AND REDUCING THE GENERATION OF FIBROBLAST GROWTH FACTOR 23 (FGF23). INCREASED 1,25 DIHYDROXYVITAMIN D LEVELS ARISE FROM THE LOWERING OF FGF23 LEVELS, WHICH ENHANCES BONE MINERAL DENSITY.RENAL ERYTHROPOIETIN PRODUCTION IS ALSO STIMULATED WHEN FGF23 ACTIVITY IS BLOCKED. FC ALSO IMPROVES IRON ABSORPTION AND UTILISATION IN THE INTESTINE, TRIGGERING RBC SYNTHESIS IN THE BONE MARROW AND BOOSTING HAEMOGLOBIN (HGB) LEVELS AND CARDIAC FUNCTIONAL CAPACITY. "" (MEANS "INCREASE"), "" (MEANS "INCREASE"), "" (MEANS "INCREASE") (MEANS DECREASE).

- **Ferric Maltol**

Ferric maltol is a novel iron complex made up of three maltol ligands linked to a stable trivalent iron complex[42,45].Before it is absorbed over the intestinal mucosa, the complex structure of ferric maltol is preserved[73].This improves absorption while lowering GI toxicity caused by free iron. Maltol is also thought to be useful at inhibiting iron-mediated lipid peroxidation and reducing oxidative stress[55].Furthermore, early findings from a phase 3 study demonstrated that oral ferric maltol was non-inferior to IV ferric carboxymaltose delivery in terms of Hgb response in the treatment of IDA in IBD patients[72].

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 1047-1065 www.ijprajournal.com ISSN: 2456-4494

The AEGIS-CKD experiment (Study with Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease) was a multicenter, phase 3 randomised, placebo-controlled trial to see if ferric maltol may help patients with NDD-CKD. The most important findings showed that oral ferric maltol (30 mg twice day) was superior to a placebo in boosting Hgb levels after 16 weeks of therapy. Additionally, Hgb levels in the ferric maltol therapy group were steady throughout a 36-week follow-up period. The AEGIS-CKD research found that oral ferric maltol is a potentially safe and effective therapy for people with chronic kidney disease[65-70].

- **Heme Iron Polypeptide**

HIP is a next-generation oral iron that exploits the heme porphyrin ring to deliver iron to absorption sites via a membrane protein on the intestinal mucosa called heme carrier protein 1. Oral HIP can be better absorbed in individuals with CKD and chronic inflammation than nonheme iron transferred into the body through DMT1 altered by hepcidin[55].

To assess the effects of oral HIP supplementation as a substitute for IV iron therapy, Nissenson et al. conducted a prospective study on HD patients who had been undergoing maintenance IV iron therapy[15-30].The authors found that oral HIP medication might successfully replace IV iron therapy in most HD patients and maintain acceptable Hgb levels without concurrent IV iron therapy after a six-month research period. This therapy was linked to a considerable boost in ESA effectiveness[70].

These findings show that orally administered HIP might be a viable alternative for iron supplementation in HD patients on ESA medication[62].

In conclusion, while early clinical data in healthy individuals suggests that orally administered HIP has superior bioavailability and tolerability compared to nonheme iron, current evidence shows that the effects of HIP administration on Hgb level, TSAT, and required EPO dose in patients with CKD who have anaemia are not significantly different from those of IV iron or orally administered nonheme iron in patients with CKD who have anaemia. HIP is linked with low ferritin levels, in contrast to conventional iron agents[12,25,34,40].

Furthermore, the price of HIP is much greater than that of nonheme iron treatments. Before HIP is extensively used for iron supplementation in individuals with CKD, a larger investigation is required[65,73].

- **Sucrosomial Iron**

A phospholipid bilayer and a sucrosomial shell protect ferric pyrophosphate in SI, a novel oral iron formulation. Iron may be absorbed by a variety of mechanisms (endocytosis, the paracellular route, and the M cells of Peyer's patches), all of which are independent of DMT1 on the enterocyte surface[68,70,72].

In M cells, the unique route of absorption allows iron to reach the lymphatic system rather than the bloodstream. Because this formulation bypasses the traditional iron absorption pathway, it has a high bioavailability.In an open-label RCT on patients with NDD-CKD, Pisani et al. compared SI to IV ferrous gluconate delivery in terms of anaemia amelioration[71,72,73].

The results showed that both methods may raise Hgb levels, but IV iron delivery had a bigger effect. Hgb levels in the group receiving IV iron supplementation remained steady when supplementation was stopped, whereas those in the SI group reverted to baseline. The SI group experienced fewer adverse effects, but IV iron delivery had a stronger effect on iron replenishment[50-57].

- **Intravenous Iron Supplementation: Recent Advances**

Patients who are unable to tolerate oral iron treatment or who are undergoing HD should get IV iron. Iron sucrose, low- and high-molecular-weight dextrans, and sodium ferric gluconate are among the IV iron complexes available. The use of these standard IV iron preparations, on the other hand, necessitates close attention to infusion responses. To check for an allergic response, the patient must be observed for 60 minutes following the IV infusion. Furthermore, the testing dosage is indicated for the first time administration of typical IV iron treatments[18,19,26,30].

Three new-generation IV iron compounds (ferumoxytol, iron isomaltoside 1000, and ferric carboxymaltose) have recently been discovered and are already being utilised widely in clinical practise. The great stability of the carbohydrate shell, which prevents uncontrolled release of harmful free iron and allows for complete replacement dosages in one or two IV iron infusions, is the most beneficial feature of these agents. These preparations can be given as a single infusion without the requirement for a testing dosage due to their modest immunological activity[31,33,34].

The redox potential of a material is described as its proclivity to be reduced, resulting in the generation of reactive oxygen species

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 1047-1065 www.ijprajournal.com ISSN: 2456-4494

following exposure to reducing agents such as excess ascorbic acid. These novel IV iron agents have a stable polynuclear iron core with a low redox potential, which reduces the likelihood of oxidative stress responses[36,39,42].Ferric pyrophosphate citrate (FPC) is an appropriate choice recommended for maintenance iron treatment in adult patients on HD to minimise hepcidin-induced iron sequestration and oxidative damage following IV iron infusion[55].

Small quantities of iron are immediately transported to transferrin, bypassing the reticuloendothelial system and minimising the development of non-transferrin-bound iron (NTBI), which can cause reactive oxygen species and cellular damage[58].Intradialytic iron supplementation with FPC was shown to safely maintain Hgb levels and significantly reduce the required ESA dose in patients undergoing long-term HD in two multicenter, randomised, placebo-controlled, phase 3 clinical trials, The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 1 and 2). Table 4 provides a review of current IV iron compositions[65-69].



FIG5:FPC-BOUND TRANSFERRIN CRYSTAL STRUCTURE. THE N-TERMINAL LOBE OF HUMAN TRANSFERRIN COUPLED TO FPC IS DEPICTED IN GREY RIBBONS WHILE THE C-TERMINAL LOBE IS DISPLAYED IN GREEN RIBBONS IN A 2.6-A RESOLUTION CO-CRYSTAL STRUCTURE. ORANGE SPHERES REPRESENT IRON ATOMS. STICK RENDERINGS OF PYROPHOSPHATE AND CARBONATE ARE PRESENTED. THE LINKER CONNECTING THE N- AND C-LOBES WAS DISORDERED AND TAGGED, AS WELL AS THE N- AND C-TERMINI. B IRON AND PYROPHOSPHATE WERE BOUND BY THE N-LOBE. C THE C-LOBE IS IRON AND CARBONATE BONDED. INDIVIDUAL AMINO ACIDS ARE INDICATED IN THE 2|F0| - |FC| ELECTRON DENSITY MAPS, WHICH ARE PRESENTED IN BLUE MESH CONTOURED AT 1.0 R.

- **Medications to lower cholesterol levels**

To reduce your cholesterol, your doctor may prescribe statin drugs. High levels of poor cholesterol are common in those with chronic renal disease, which can raise the risk of heart disease[19,20].

- **Medications to protect your bones**

Supplementing with calcium and vitamin D can help prevent weak bones and reduce your risk of fracture. You may also take phosphate binder medicine to reduce the quantity of phosphate in your blood and protect your blood vessels against calcium deposits (calcification)[11,13].

- **A lower protein diet to minimize waste products in your blood**

Your body produces waste products when it consumes protein from food, which your kidneys must filter from your blood. Your doctor may advise you to consume less protein to lessen the amount of work your kidneys have to do. A qualified dietician can advise you on how to reduce your protein intake while maintaining a balanced diet[65-71].

❖ **End-of-life renal disease treatment:**

End-stage renal disease occurs when your kidneys can't keep up with waste and fluid clearance on their own and you develop total or near-complete kidney failure. You'll require dialysis or a kidney transplant at that time[45,62].

- **Dialysis:**

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 1047-1065 www.ijprajournal.com ISSN: 2456-4494

When your kidneys are no longer able to do so, dialysis is used to eliminate waste products and excess fluid from your blood[44,46].A machine separates waste and extra fluids from your blood during hemodialysis.

A small tube put into your belly fills your abdominal cavity with a dialysis solution that absorbs waste and excess fluids in peritoneal dialysis. The waste is carried away by the dialysis solution as it drains from your body[65,67].

- **Kidney transplant:**

A kidney transplant is when a healthy kidney from a donor is surgically implanted into your body. Kidneys can be transplanted from either deceased or living donors[73].

To prevent your body from rejecting the new organ after a transplant, you'll need to take drugs for the rest of your life. A kidney transplant does not need you to be on dialysis[11,12,15].

A third option for those who do not want dialysis or a kidney transplant is to manage renal failure using conservative methods. Symptom control, advance care planning, and comfort care are likely to be among the conservative measures taken (palliative care)[56,62].

II. DISCUSSION

Chronic kidney disease (CKD) is described by a latest "Kidney Disease Enhancing Worldwide Achievements" (KDIGO) regulations as the appearance about an estimated glomerular filtration rate (EGFR) of less than 60ml/min/1.73m2 (within at least 3 months) according to computed tomography. But GFR of 60ml/min/1.73m2 does not always detect the presence of CKD though there is indication of nephro structural harm.

Most common causes of CKD are hypertension, chronic glomerulonephritis, chronic pyelonephritis, chronic anti-inflammatory drug usage, autoimmune illnesses, kidney disorders, prolonged acute renal disease etc. Many studies have shown that CKD develops from phase 1 to phase 5 by the eGFR test result tPA/PAI-1, MMP-9, indoxyl sulphate, p-cresyl sulphate,TGF-b1, Tenascin-C, PAI, ANG-II, and concomitant diseases, such as hypertension and diabetes. Around the age of 30, the glomerulus is replaced with fibrous tissue (glomerulosclerosis)

subendothelial deposits of hyaline tissue and collagen in the arterioles, thickening of the intima, medial atrophy, and sympathetic vascular impulse failure according to Indian data.

There is Decrement in sodium reabsorption, which leads to increased fractional sodium excretion in elderly patients,and a reduce of in both kidney plasma concentration and response to stimulus, resulting in medullary hypotonicity and a lower urine concentration capacity. Symptoms like nausea and vomiting,loss of appetite,itching,uncontrollable high blood pressure,cramps and twitches,insomnia, bad breath,fatigue, numbness in your limbs,fluid buildup in your lungs or other areas,vitamin D deficiency, which can affect your bone health etc have been seen. Blood test, urine test, imaging test are performed. Also some studies shows Biopsy of kidney tissue as a tool in diagnose of CKD. Blocking the RAAS with ACE inhibitors or ARBs have shown to slow the course of CKD. Mr Jeffrey M. Turner Showed that Diuretics are medications that keep your body's fluid balance in check. Growth hormone supplementation in maintenance HD patients resulted in a substantial drop in CRP and homocysteine, as well as an increase in blood HDL cholesterol and transferrin, according to a large multicenter randomised controlled experiment.

In preclinical studies of CKD characterised by glomerular capillary hypertension,ACE inhibitors diminished glomerular capillary pressure more than combined therapy with hydralazine, reserpine, and a diuretic and also slowed disease progression more effectively. Injured kidneys generate less erythropoietin (EPO) and less oxygen reach tissues. Hence Ferric pyrophosphate citrate injection is an iron replacement medication used to treat iron deficiency anaemia in patients with chronic renal disease who are on dialysis (CKD). Iron sucrose, low- and high-molecular-weight dextrans, and sodium ferric gluconate are some IV iron present.

Those patients who are unable to tolerate oral iron treatment or who are undergoing HD undergo IV iron. They show less oxidative stress studied by M Sharifi-Rad as they have low redox potential. The study publishein RD Cançado showed the carbohydrate shell prevents uncontrolled release of harmful free iron and allows for complete replacement dosages in one or two IV iron infusions which is the best parameter.

Ferric pyrophosphate citrate is an iron replacement product indicated for the replacement of iron to maintain hemoglobin in adult patients

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 1047-1065 www.ijprajournal.com ISSN: 2456-4494

with hemodialysis-dependent chronic kidney disease (HDD-CKD).

Ferric pyrophosphate citrate (FPC, Triferic®) donates iron directly to transferrin, bypassing the reticuloendothelial system and avoiding iron sequestration. Administration of FPC via dialysate or intravenously (IV) may provide a suitable therapeutic option to current IV iron preparations for these patients.All the discussion above shows that IV iron ferric pyrophosphate has promising role in iron definitely anaemia in patients with CKD.

III. CONCLUSION

Chronic kidney disease (CKD) is a prevalent clinical condition among the elderly, and it is linked to an increased risk of morbidity and mortality.

Iron deficiency is a major cause of anaemia in children with chronic renal disease who are on hemodialysis (CKD-5HD). Iron is donated directly to transferrin by ferric pyrophosphate citrate (FPC, Triferic®), circumventing the reticuloendothelial system and eliminating iron accumulation.

In addition, a detailed overview is included in this review about CKD, It's Classification, mechanisms,Symptoms,Diagnosis.

Iron deficiency is a major cause of anaemia in elderly with chronic renal disease who are on hemodialysis (CKD-5HD). Iron is donated directly to transferrin by IV ferric pyrophosphate citrate (FPC, Triferic®), bypassing the reticuloendothelial system and avoiding iron sequestration.

IV Ferric pyrophosphate citrate is used to treat iron deficiency and loss of haemoglobin, as well as to lower the amount of erythropoiesis-stimulating agent (ESA) needed to maintain target haemoglobin levels.

REFERENCES

[1]. Kalantar-Zadeh, K., Jafar, et al (2021). "Chronic kidney disease". The Lancet, 398(10302), 786-802.

[2]. Kanbay, M., Bulbul, et al (2021). "Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease". Journal of nephrology, 34(3), 649–659.

[3]. Lyerly M. J. (2021). "Acute Stroke Care for Patients with Chronic Kidney Disease". Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 30(9), 105725.

[4]. Lee, J. Y.,et al(2021). "Blood pressure control in patients with chronic kidney disease". The Korean journal of internal medicine, 36(4), 780–794.

[5]. Naber, T., & Purohit, S. (2021). "Chronic Kidney Disease: Role of Diet for a Reduction in the Severity of the Disease". Nutrients, 13(9), 3277.

[6]. Lanot, A., Kottler, D., et al (2021). "Pruritassocié à la maladierénalechronique [Pruritus associated chronic kidney disease]". Nephrologie&therapeutique, 17(7), 488–495.

[7]. Tsai, H. J.,et al (2021). "Environmental Pollution and Chronic Kidney Disease". International journal of medical sciences, 18(5), 1121–1129.

[8]. Laffin, L. J.,et al (2021). "Intersection Between Chronic Kidney Disease and Cardiovascular Disease". Current cardiology reports, 23(9), 117.

[9]. Neyra, J. A.,et al(2021). "Acute Kidney Disease to Chronic Kidney Disease". Critical care clinics, 37(2), 453–474.

[10]. Ammirati A. L. (2020). "Chronic Kidney Disease". Revista da Associacao Medica Brasileira (1992), 66Suppl 1(Suppl 1), s03–s09.

[11]. Charles, C., et al (2020). "Chronic Kidney Disease". Primary care, 47(4), 585–595.

[12]. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (2020). KDIGO 2020 "Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease". Kidney international, 98(4S), S1–S115.

[13]. Luo, S., & Grams, M. E. (2020). "Epidemiology research to foster improvement in chronic kidney disease care". Kidney international, 97(3), 477–486.

[14]. Duni, A., Dounousi, E.,et al(2020). "Hypertension in Chronic Kidney Disease: Novel Insights". Current hypertension reviews, 16(1), 45–54.

[15]. Li, L.; Nakano, D.;et al(2020). "Effects ofpost-renal anemia treatment with the HIF-PHD inhibitor molidustat on adenine-induced renal anemia and kidney disease inmice". J. Pharmacol. Sci.144, 229–236.

[16]. Kumar, A.; (2020) "Brookes, M.J. Iron Therapy in Inflammatory Bowel Disease. Nutrients" 12, 3478.

[17]. Khoury, A.; Pagan, K.A.; et al(2020) "A New Oral Iron Formulation for the

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 1047-1065 www.ijprajournal.com ISSN: 2456-4494

Treatment of Iron Deficiency inAdults. Ann. Pharmacother"

[18]. Block, G.A.; Chertow, G.M.;et al(2020) "Fibroblast growth factor 23 as a riskfactor for cardiovascular events and mortality in patients in the EVOLVE trial". Hemodial. Int.

[19]. Wang, Y. N. et al (2019). "Chronic kidney disease: Biomarker diagnosis to therapeutic targets. Clinicachimica acta"; international journal of clinical chemistry, 499, 54–63.

[20]. Tótoli, C., Carvalho,et al (2019). "Associated factors related to chronic kidney disease progression in elderly patients". PloS one, 14(7), e0219956.

[21]. Ostuni, M., &Musso,etal (2019). "Usefulness of frailty evaluation for handling chronic kidney disease elderly patients: a review and original proposal". International urology and nephrology, 51(3), 461-465

[22]. Centers for Disease Control and Prevention. (2019). "Chronic kidney disease in the United States", (2019). Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention.

[23]. Chen, N.; Hao, C.;et al(2019). "Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis". N. Engl. J. Med.381, 1011–1022.

[24]. Chen, N.; Hao, C.; et al(2019). "Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis". N. Engl. J. Med. 381, 1001–1010.

[25]. Fishbane, S.; El-Shahawy et al(2019) "A phase 3, randomized, double-blind, placebo-controlled, international study of roxadustat efficacy in patients with non-dialysis-dependent (NDD) CKD and anemia". In Proceedings of the American Society of Nephrology Kidney Week, Washington, DC, USA.

[26]. Fishbane, S.; El-Shahawy et al(2019) "An international, phase 3, randomized, open-label, active-controlled study of roxadustat for anemia in dialysis-dependent CKD patients". In Proceedings of the American Society of Nephrology Kidney Week, Washington, DC, USA.

[27]. Jain, M.; Joharapurkar, A.; et al(2019)"Pharmacological inhibition of prolylhydroxylase protects against inflammation-induced anemia via efficient erythropoiesis and hepcidin downregulation". Eur. J.Pharmacol.,843, 113–120.

[28]. Abbati, G.; Incerti, F.; et al(2019)"Safety and efficacy of sucrosomialiron in inflammatory bowel disease patients with iron deficiency anemia". Intern. Emerg. Med.14, 423–431.

[29]. Kim, K. S., Park,etal (2018). "Higher prevalence and progression rate of chronic kidney disease in elderly patients with type 2 diabetes mellitus". Diabetes & metabolism journal, 42(3), 224-232.

[30]. Formica, M., Politano, P., et al (2018). "Acute kidney injury and chronic kidney disease in the elderly and polypharmacy". Blood purification, 46(4), 332-336.

[31]. Chen, S. Y., et al (2018). "Traffic-related air pollution associated with chronic kidney disease among elderly residents in Taipei City". Environmental pollution, 234, 838-845.

[32]. Pratt, R.; Handelman, G.J.;et al(2018), "Ferric pyrophosphate citrate: Interactions with transferrin. Biometals",31,1081–1089.

[33]. Shah, A.; Dobrovolskaia, M.A.(2018) " Immunological effects of iron oxide nanoparticles and iron-based complex drug formulations:Therapeutic benefits, toxicity, mechanistic insights, and translational consideration"s. Nanomedicine, 14, 977–990.

[34]. Girelli, D.; Ugolini, S.; et al(2018) "Modern iron replacement therapy: Clinical and pathophysiological insights". Int. J. Hematol. 107, 16–30.

[35]. Girndt M. (2017). "Diagnostik und Therapie der chronischenNierenerkrankung [Diagnosis and treatment of chronic kidney disease]". Der Internist, 58(3), 243–256.

[36]. Paniagua-Sierra, J. R. et al(2017). "Enfermedad renal crónica [Chronic kidney disease]". Revista medica del Instituto Mexicano del Seguro Social, 55(Suppl 2), S116–S117.

[37]. Mikhail, A., Brown, C. et al(2017). "Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease". BMC nephrology, 18(1), 345.

[38]. Dhondup, T., & Qian, Q. (2017). "Electrolyte and Acid-Base Disorders in Chronic Kidney Disease and End-Stage Kidney Failure". Blood purification, 43(1-3), 179–188.

[39]. Wanner, C., &Ketteler, M. (2017)." ChronischesNierenversagen [Chronic

Kidney Disease]". Deutsche medizinischeWochenschrift (1946), 142(3), 193–196.
[40]. Wongrakpanich, S., Susantitaphong, P.,etal (2017). "Dialysis therapy and conservative management of advanced chronic kidney disease in the elderly: a systematic review". Nephron, 137(3), 178-189.
[41]. Pereira, R. M. D. P., Batista, M. A.,etal (2017). "Quality of life of elderly people with chronic kidney disease in conservative treatment". Revistabrasileira de enfermagem, 70, 851-859.
[42]. Porter, C. J., Moppett, I. K.,etal (2017). "Acute and chronic kidney disease in elderly patients with hip fracture: prevalence, risk factors and outcome with development and validation of a risk prediction model for acute kidney injury". BMC nephrology, 18(1), 1-11.
[43]. Kalantar-Zadeh, K.,etal (2017). "Nutritional management of chronic kidney disease". New England Journal of Medicine, 377(18), 1765-1776.
[44]. Webster, A. C., Nagler,et al (2017). "Chronic kidney disease". The lancet, 389(10075), 1238-1252.
[45]. Romagnani, P., Remuzzi, G.,et al (2017). "Chronic kidney disease". Nature reviews Disease primers, 3(1), 1-24.
[46]. Delles, C., &Vanholder, R. (2017). "Chronic kidney disease". Clinical science (London, England : 1979), 131(3), 225–226.
[47]. Shen, Y., Cai, R.,et al (2017). "Diabetes mellitus as a risk factor for incident chronic kidney disease and end-stage renal disease in women compared with men: a systematic review and meta-analysis". Endocrine, 55(1), 66–76.
[48]. Mafodda, A.; Giuffrida, D.;et al(2017) "Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: A pilot study". Support. Care Cancer, 25, 2779–2786.
[49]. Stein, J.; Aksan, A.;et al(2017) "Management of inflammatory bowel disease-related anemia and iron deficiency with specific reference to the role of intravenous iron in current practice". Expert Opin. Pharmacother. 18, 1721–1737.
[50]. Mehta, R.; Cai, X.; et al(2017) "Fibroblast Growth Factor 23 and Anemia in the Chronic Renal Insufficiency Cohort Study". Clin. J. Am. Soc. Nephrol. 12, 1795–1803
[51]. Fishbane, S.; Shah, H.H.(2017) " Ferric pyrophosphate citrate as an iron replacement agent for patients receiving hemodialysis". Hemodial.Int. 21 (Suppl. 1), S104–S109.
[52]. Fishbane, S.; Block, G.A.; et al(2017) "Effects of Ferric Citrate in Patients withNondialysis-Dependent CKD and Iron Deficiency Anemia". J. Am. Soc. Nephrol. 28, 1851–1858.
[53]. Ferenbach, D. A. et al (2016). "Acute kidney injury and chronic kidney disease: From the laboratory to the clinic). Nephrologie&therapeutique, 12 Suppl 1(Suppl 1), S41–S48.
[54]. Silva, S. M. D.,et al (2016). ""Social support of adults and elderly with chronic kidney disease on dialysis". Revistalatino-americana de enfermagem, 24.
[55]. Ellam, T., Twohig, H.,et al (2016). "Chronic kidney disease in elderly people: disease or disease label?". Bmj, 352.
[56]. Becherucci, F., Roperto, R. M.,et al (2016). "Chronic kidney disease in children". Clinical kidney journal, 9(4), 583-591.
[57]. Zhang, L., Long, J.,et al (2016). "Trends in chronic kidney disease in China". New England Journal of Medicine, 375(9), 905-906.
[58]. Vassalotti, J. A., Centor, R.,et al(2016). "Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician". The American journal of medicine, 129(2), 153–162.e7.
[59]. Panwar, B.; Gutiérrez, et al(2016) "Disorders of Iron Metabolism and Anemia in Chronic Kidney Disease. Semin. Nephrol". 36,252–261.
[60]. Pugh, C.W.(2016) " Modulation of the Hypoxic Response". Adv. Exp. Med. Biol. 903, 259–271.
[61]. Balla, S.; Ismail,A.(2016) "Impact of Hemodialysis on Serum Zinc and Copper Level in CKD Patients". J. App. Pharm. Sci. 6, 165–168.
[62]. Ratcliffe, L.E.; Thomas, W.; et al(2016). "Diagnosis and Management of Iron Deficiency in CKD: A Summary of the NICE Guideline Recommendations and Their Rationale". Am. J. Kidney Dis.67, 548–558.
[63]. Hanudel, M.R.; Chua, K.; et al(2016) "Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin

knockout mice". Am. J. Physiol. Ren. Physiol. 311, F1369–F1377.
[64]. Drawz, P., et al(2015). "Chronic kidney disease". Annals of internal medicine, 162(11), ITC1–ITC16.
[65]. Ponticelli, C., Sala, G.,et al (2015, May). "Drug management in the elderly adult with chronic kidney disease: a review for the primary care physician". In Mayo Clinic Proceedings (Vol. 90, No. 5, pp. 633-645). Elsevier.
[66]. Drawz, P., & Rahman, M. (2015). "Chronic kidney disease. Annals of internal medicine", 162(11), ITC1-ITC16.
[67]. Gargiulo, R., Suhail, F.,et al(2015). "Hypertension and chronic kidney disease". Disease-a-month : DM, 61(9), 387–395.
[68]. Said, A., Desai, C.,et al (2015). "Chronic kidney disease". Disease-a-month : DM, 61(9), 374–377.
[69]. Block, G.A.; Fishbane, S.; et al(2015)"A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3–5". Am. J. Kidney Dis.65, 728–736.
[70]. Umanath, K.; Jalal, D.I.; et al(2015). "Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD". J. Am. Soc. Nephrol.,26, 2578–2587.
[71]. Lewis, J.B.; Sika, M.; et al(2015). "Ferric citrate controls phosphorus and delivers iron in patients on dialysis". J. Am. Soc. Nephrol. 26, 493–503.
[72]. Chen, C.H.; Shu, K.H.; et al(2015) "Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload".Hematology 20, 304–310.
[73]. Borgna-Pignatti, C.; Marsella, M.(2015) " Iron Chelation in Thalassemia Major". Clin. Ther. 37, 2866–2877.